A Phase 4 interventional study of Romosozumab and Zoledronate in Osteoporosis, sponsored by University of Aarhus. Recruiting at 1 site in Denmark. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by University of Aarhus · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.
Among the 20 studies testing romosozumab in Osteoporosis, this one is the 4th largest by planned enrollment, is one of 3 that started in 2023, is one of 10 in phase 4, and was the 14th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
Sahlgrenska University Hospital · Sites in Sweden
Ages 60+ · Women only
Tuen Mun Hospital · Sites in Hong Kong
Ages 18+
Marmara University · Sites in Turkey
Ages 55–85 · Women only
By country, each count listing its studies:
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 270 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 80 across the 20 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
15 studies in Osteoporosis by University of Aarhus: 1 open now, 1 under way, none of them phase 3. Of 13 finished, 1 (8%) have results posted.
Among the 15 studies in Osteoporosis by University of Aarhus, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 4, and was the 15th registered.
University of Aarhus’s Osteoporosis studies by the year they started, since 1990.
3 of the studies testing romosozumab in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05775094Memorial Sloan Kettering Cancer CenterA Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | 2027-03 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT07757373Tuen Mun HospitalRomosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing romosozumab in Osteoporosis, from their registry updates:
Among University of Aarhus’s 15 in Osteoporosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
OPTIMIST is a two-year, randomised, active controlled, open-label, multicentre intervention trial. OPTIMIST includes 3 treatment groups each comprising combinations of romosozumab (ROMO) and zoledronate (ZOL) treatment used in standard doses (210 mg monthly (sc) and 5 mg yearly (iv), respectively).
The study will investigate if it is possible to maximize the effect of romosozumab by giving it in 2 periods of 6 months interrupted by zoledronate for 12 months compared to romosozumab for 12 months uninterrupted followed by zoledronate for 12 months. The investigators will also evaluate if 6 months of romosozumab followed by 18 months of zoledronate is non-inferior to the standard regimen of romosozumab for 12 months followed by zoledronate for 12 months.
Recent clinical trials have demonstrated the benefit of bone anabolic treatment over no treatment or antiresorptive treatment in terms of increasing bone mineral density (BMD) and reducing fracture risk for patients with osteoporosis. However, the bone anabolic treatment is expensive and therefore restricted to a limited group of patients.
This study is based on the hypothesis that treatment with romosozumab for 6 months, zoledronate for 12 months, and romosozumab for 6 months results in larger gains in bone mineral density than treatment regimens based on romosozumab treatment for 6 or 12 months followed by zoledronate for a total of 24 months of treatment due to reappearance of the bone anabolic effect of romosozumab upon retreatment.
The OPTIMIST study is a two-year, randomised, active controlled, open-label, intervention trial. The study includes 270 postmenopausal women who will be randomised to 3 groups. Group 1 (n=90) will receive romosozumab for 12 months followed by zoledronate for 12 months. Group 2 (n=90) will receive romosozumab for 6 months followed by zoledronate for 12 months and romosozumab for 6 months. Group 3 (n=90 ) will receive romosozumab for 6 months followed by zoledronate for 18 months.
The investigational drugs in this study are romosozumab 210 mg/2,34 mL and zoledronate 5 mg/100 mL
This study will include 270 treatment naïve postmenopausal women. When inclusion and exclusion criteria have been reviewed, and the participant meets the requirements for study participation and continues to participate in the study, the patients will be randomized 1:1:1 Data will be registered in RedCAP (eCRF) and site monitoring assessed by the local Good Clinical Practice unit (GCP-unit).
The patients will be recruited from the outpatient clinics and the Dual-Energy X-ray Absorptiometry (DXA) units to which patients are referred from their general practitioner or fracture liaison services (FLS) at:
Department of Endocrinology, Odense University Hospital Department of Endocrinology and Internal Medicine, Aarhus University Hospital Department of Endocrinology, Køge Hospital Department of Endocrinology, Hvidovre Hospital Department of Endocrinology, Bispebjerg Hospital
During the intervention phase, there will be obtained fasting blood test, high-resolution peripheral quantitative computed tomography (HR-pQCT),Oral Glucose Tolerance Test (OGTT), DXA, Vertebral fracture assessment (VFA) and biochemistry at different time stamps. From 105 patients there will be obtained bone marrow aspirates and performed jamshidi bone biopsies.
The study will therefore show if it would be possible to treat twice as many patients for the same prize but also if the treatment for 12 months can be optimized. The knowledge about the optimal use of romosozumab will be included in an update of osteoporosis treatment guidelines. This will lead to optimized treatment of patients with severe osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
90 patients 12 months of romosozumab (ROMO) followed by 12 months of zoledronate (ZOL)
Drug: Romosozumab · Drug: Zoledronate
90 patients 6 months of romosozumab followed by 12 months of zoledronate and lastly 6 months of romosozumab.
Drug: Romosozumab · Drug: Zoledronate
90 patients 6 months of romosozumab followed by 18 months of zoledronate .
Drug: Romosozumab · Drug: Zoledronate
Romosozumab 210 mg/2.34 ml from baseline to month 11
Also known as: Evenity
5 mg/100 ml at month 12
210 mg/2.34 ml from baseline to month 5 and from month 18 to month 23
Also known as: Evenity
5 mg/100 ml at month 6
210 mg/2.34 ml from baseline to month 5
Also known as: Evenity
5 mg/100 ml at month 5 and month 18
Change in total hip BMD
Change in total hip BMD
Time frame: 24 months
Changes in femoral neck BMD
Change in femoral neck BMD
Time frame: 24 months
Changes in trabecular bone volume fraction (bone volume/tissue volume, BV/TV) and cortical porosity measured by high-resolution peripheral quantitative computed tomography (HR-pQCT)
Mean percent change in trabecular bone volume fraction and cortical porosity measured by HR-pQCT at the radius and tibia
Time frame: 24 months
Change in spine BMD
Change in spine BMD
Time frame: 24 months
Bone resorption and formation -Changes in P1NP (procollagen type I N-terminal propeptide)
Changes in P1NP (blood sample)
Time frame: 1, 3, 6, 12, 18, 19, 21 and 24 months
Bone resorption and formation - Changes in CTX
Changes in cross-linked C-terminal telopeptide (CTX) (blood sample)
Time frame: 1, 3, 6, 12, 18, 19, 21 and 24 months
Bone resorption and formation - Changes in collagen
Bone turnover marker (BTM) collagen (blood sample)
Time frame: 1, 3, 6, 12, 18, 19, 21 and 24 months
Bone remodelling and modelling assessed using bone histology (jamshidi biopsy)
Investigate the activation of bone remodelling and modelling-based bone formation by ROMO assessed by bone histology (jamshidi biopsy) at 1 (any group), 6 (any group), 18 (group 3), 19 (group 2) and 24 (group 2) months. Biopsies will be obtained from 15 participants at each timepoint. Investigate the depletion of osteoprogenitor cells during ROMO treatment assessed by molecular bone histology and single-nucleic transcriptomics.
Time frame: Month 1, 6, 18, 19, 24
Investigate the number and composition of osteoprogenitor cells in the bone marrow during the first and second romosozumab treatment.
Investigate the number and composition of osteoprogenitor cells in the bone marrow during the first and second romosozumab treatment. Bone marrow (BM) aspirates will be obtained by aspiration of the iliac crest (10-15 ml) during the jamshidi biopsy.
Time frame: Month 1 and 19
Effect of romosozumab on glucose metabolism and insulin sensitivity (measurement of fasting glucose)
Change in fasting glucose (mmol/l) Blood sample
Time frame: Month 1 and 3
Effect of romosozumab on glucose metabolism and insulin sensitivity (measurement of Hba1c)
Change in glycated haemoglobin (Hba1c) (mmol/mol) Blood sample
Time frame: Month 1 and 3
Effect of romosozumab on glucose metabolism and insulin sensitivity (ogtt)
Change in oral Glucose tolerance test (OGTT) Data is collected by giving glucose and blood samples are taken afterward to determine the patients blood sugar (mmol/l) how quickly it is cleared from the blood
Time frame: Month 1 and 3
Effect of romosozumab on glucose metabolism and insulin sensitivity (HOMA-IR)
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) calculated from fasting blood sugar (blood sample) and insulin levels (blood sample) by following equation: (\[insulin (μU/ml)\] × \[fasting glucose (mmol/l)\]/22,5)
Time frame: Month 1 and 3
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Aug 2030, 82 months after the start.
Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's planned 82 months is above that.
Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Romosozumab · Zoledronic Acid